AGM/EGMJun 25, 2026, 04:33 PM
Cellectis Shareholders Approve All 30 Resolutions at General Meeting
AI Summary
Cellectis S.A. shareholders approved all 30 proposed resolutions at the Combined General Meeting held on December 31, 2025. Key approvals included the company's 2025 financial statements, the renewal of four Board of Directors members, and authorizations for share buybacks and capital reductions. Shareholders also granted the Board broad delegations of authority for future capital increases, including those with cancellation of preferential subscription rights for various investor categories and an "At-the-market" program. All resolutions were carried, demonstrating strong shareholder support for the company's proposals.
Key Highlights
- Approved 2025 annual financial statements with 99.94% of votes in favor.
- Approved 2025 consolidated financial statements with 99.94% of votes in favor.
- Renewed four Board of Directors members with approval rates ranging from 94.06% to 99.73%.
- Authorized share buyback program with 99.42% of votes in favor.
- Authorized capital reduction by cancelling shares with 99.46% of votes in favor.
- Delegated authority for capital increases with preferential rights cancellation for specific investors (e.g., 97.80% For for health/biotech).
- Delegated authority for capital increases via an "At-the-market" (ATM) program with 97.90% of votes in favor.
- Approved authorization for share options and free share allocations to employees/officers with 99.37% of votes in favor.
Price Impact
More from CLLS